Organon & Co. (OGN): Total Assets
$12.87B
As of 2025-12-31
$13.18B
As of 2026-06-30
+5.5%
3-year compound annual growth
+4.9%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $12.87B | -1.8% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $13.10B | +8.6% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $12.06B | +10.1% | 2025-11-10, Balance as of period end |
| 2022-12-31 | $10.96B | +2.6% | 2024-02-26, Balance as of period end |
| 2021-12-31 | $10.68B | +5.7% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $10.11B | n/a | 2022-03-21, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Organon & Co. (OGN) | 2025-12-31 | $12.87B | -1.8% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $8.19B | +38.3% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $13.36B | +5.9% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $11.66B | -2.9% |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $8.54B | -11.5% |
| Zoetis Inc. (ZTS) | 2025-12-31 | $15.47B | +8.6% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $26.37B | -0.6% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $4.97B | +17.1% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $7.59B | +8.7% |
Compare OGN, ONC, ELAN, JAZZ side by side · Screen every company in Pharmaceutical Preparations ↗